Pregnancy is a state of high metabolic demand. Fasting diverts metabolism to fatty acid oxidation, and the fasted response occurs much more rapidly in pregnant women than in non-pregnant women. The product of the imprinted DLK1 gene (delta-like homolog 1) is an endocrine signaling molecule that reaches a high concentration in the maternal circulation during late pregnancy. By using mouse models with deleted Dlk1, we show that the fetus is the source of maternal circulating DLK1. In the absence of fetally derived DLK1, the maternal fasting response is impaired. Furthermore, we found that maternal circulating DLK1 levels predict embryonic mass in mice and can differentiate healthy small-for-gestational-age (SGA) infants from pathologically small infants in a human cohort. Therefore, measurement of DLK1 concentration in maternal blood may be a valuable method for diagnosing human disorders associated with impaired DLK1 expression and to predict poor intrauterine growth and complications of pregnancy.
Adaptations to maternal carbohydrate and lipid metabolism occur during pregnancy to ensure a continuous supply of nutrients to the fetus 1 . In late gestation, fasting rapidly diverts maternal metabolism to fatty acid oxidation, and reductions in maternal plasma glucose and insulin levels combined with elevated fatty acid and ketone levels are seen in fasted pregnant women hours before these changes are observed in non-pregnant women-a phenomenon known as 'accelerated starvation' (ref. 2) .
DLK1 is the product of an imprinted gene that is predominantly expressed from the paternally inherited chromosome during fetal development 3, 4 . It is a single-pass transmembrane protein that can be cleaved by extracellular proteases to give rise to a circulating form 5 . This soluble moiety reaches a high concentration in the maternal circulation during late pregnancy [6] [7] [8] . DLK1, also referred to as fetal antigen 1 (FA1) or preadipocyte factor 1 (PREF 1 ), is known to have a crucial role in adipose homeostasis 9 . Our previous studies with genetically modified mice showed that DLK1 shifts nutrient metabolism toward fatty acid oxidation, both in the context of the transition from birth to weaning 10 and following high-fat feeding, in part through modulation of the growth hormone (GH) axis 11 . Because pregnancy is similarly associated with global shifts in nutrient partitioning, we hypothesized that high DLK1 levels during this period might modulate maternal metabolic adaptations.
Here we show that the fetus is the source of maternal circulating DLK1 during pregnancy. In the absence of fetally derived DLK1, maternal ketone levels are not elevated during fasting, suggesting that DLK1 is part of the accelerated starvation response. Furthermore, lack of DLK1 during the mother's development additionally impairs her ability to respond to the metabolic demands of pregnancy. We demonstrate that circulating DLK1 levels are positively associated with embryonic mass in mouse pregnancies and that DLK1 levels are significantly lower in pregnant women who go on to deliver an SGA infant. SGA is simply a descriptive term for an infant whose birth weight falls below a statistical threshold but is of clinical interest because a proportion of SGA infants are small because of fetal growth restriction (FGR) 12 . We found that there was no significant difference in DLK1 levels between healthy SGA infants and controls, but there was a highly statistically significant reduction in DLK1 levels in infants with FGR. These data support our findings in mice that reducing DLK1 dosage compromises pregnancy. Moreover, measuring DLK1 has considerable potential utility in the clinic to identify pregnancies that will require additional monitoring and obstetrical intervention.
RESULTS

Maternal circulating DLK1 is derived from the conceptus
To determine the source and function of high maternal DLK1 levels in pregnancy, we used genetically modified mice that lack a functional Fetus-derived DLK1 is required for maternal metabolic adaptations to pregnancy and is associated with fetal growth restriction 1 4 7 4 VOLUME 48 | NUMBER 12 | DECEMBER 2016 Nature GeNetics A r t i c l e s copy of Dlk1 (ref. 13 ). We first explored the effect of loss of a functional Dlk1 gene in breeding-age females. Total body mass did not vary between genotypes (wild type, null (Dlk1 m−/p− ) and Mat (maternal heterozygote; Dlk1 m−/p+ ); Supplementary Fig. 1a ), but body composition was markedly different. At 12 weeks, virgin null females had increased abdominal white adipose tissue (WAT) and reduced muscle mass in comparison to Dlk1-expressing females ( Supplementary  Fig. 1b,c) . These alterations in body composition are likely to be due to loss of Dlk1 during embryogenesis, as Dlk1-null embryos had reduced size owing to a reduction in skeletal length and lean mass from at least as early as embryonic day (E) 18.5 ( Supplementary  Fig. 1d-f) . These mice caught up to wild-type mice in weight during the preweaning period, but body composition was not normalized (Supplementary Fig. 1b,c,g ). Elevated WAT mass at 12 weeks was accompanied by an increase in serum leptin levels ( Supplementary  Fig. 1h ). In humans, high body mass index (BMI) is associated with elevated DLK1 levels 14 , suggesting that the levels of this protein might be modulated by nutritional status.
Next, we compared DLK1 levels in plasma from virgin wild-type females with the levels at E15.5 in wild-type females that had been mated to wild-type males. Plasma DLK1 levels increased approximately fivefold during the first 2 weeks of mouse pregnancy (Fig. 1a) . Because Dlk1 is expressed predominantly from the paternally inherited chromosome 3, 4 , a cross between a null mother and a wild-type father produces offspring that express Dlk1 at wild-type levels, as they all inherit an intact Dlk1 gene from their father (they are maternal heterozygotes for the deleted allele (Dlk1 m−/p+ ; Mat)). Conversely, a cross between a Dlk1-expressing mother (either a Mat or wild-type mouse) and a null father produces offspring that do not express Dlk1 (they are, respectively, homozygotes or paternal heterozygotes for the deleted allele (Dlk1 m−/p− (null) and Dlk1 m+/p− (Pat)), as maternally inherited Dlk1 is repressed by imprinting. All crosses are summarized in Figure 1b . In pregnancies where both the mother and the conceptus inherited the ablated Dlk1 gene (null × null), DLK1 could not be detected in maternal plasma (Fig. 1a,c) , confirming that there was no residual DLK1 produced from the ablated Dlk1 allele.
We conducted serial measurements of maternal plasma DLK1 levels in crosses of mice where the mother, the conceptus, or both were unable to express Dlk1 (Fig. 1b,c) . DLK1 was detected at high levels in maternal plasma only if the conceptus retained the ability to express Dlk1 (Fig. 1c) . Thus, the conceptus is the source of elevated maternal plasma DLK1 levels in pregnancy. DLK1 levels in maternal plasma began to rise between E9.5 and E11.5 in all crosses that resulted in Dlk1-expressing conceptuses (Fig. 1c) . This rise coincides with the time of formation of the definitive placenta in mice 15 .
Unexpectedly, null females crossed with wild-type males had equal or higher levels of plasma DLK1 than wild-type or Mat females crossed to wild-type males (Fig. 1d) . Because DLK1 levels are known to correlate with the number of conceptuses in the litter 6 , we investigated whether litter size was affected by maternal genotype. Consistently, null mothers had larger litters than mothers with a functional copy of Dlk1 ( Fig. 1e and Supplementary Table 1) . This difference was not due to a sampling error caused by controlling our cohort to exclude extremes of litter size and genotype ratio, as, when we pooled the data for all crosses generated, null females consistently produced approximately one additional conceptus in comparison to wild-type and Mat females (wild-type and Mat mean litter size = 7.0 ± 0.3, n = 40 litters; null mean litter size = 8.2 ± 0.3, n = 48 litters; P < 0.001, Mann-Whitney test). Appropriate maternal leptin levels are necessary for conception and survival of the early embryo 16 ; leptin increases the invasiveness of the early embryo 17 and enhances ovulation 18 . Our finding that null females had increased fecundity is consistent with the elevated leptin levels of these females (Supplementary Fig. 1h) .
When the amount of maternal plasma DLK1 per expressing conceptus was calculated, conceptuses from null × wild type crosses produced a similar amount of DLK1 as conceptuses from wild type × wild type and Mat × wild type crosses ( Fig. 1e and Supplementary  Table 1 ). However, litters where only half of the conceptuses had an intact Dlk1 allele (null × Mat crosses; Fig. 1b) produced significantly more DLK1 per conceptus than litters where all conceptuses were able to express Dlk1 (Fig. 1d, inset) .
Fetal, not placental, origin of maternal circulating DLK1
To distinguish whether the placenta or the embryo is the source of maternal plasma DLK1, we used additional models with Dlk1 dosage manipulation. We have previously described a transgenic line that recapitulates Dlk1 expression in the embryo but not in the placenta 19 (Fig. 2a) . We crossed the transgene onto a Dlk1 −/− background (null-TG) and measured transgene-specific Dlk1 expression in the embryo and placenta (Fig. 2b,c) . As expected, DLK1 expression in the embryo closely resembled that in the wild-type state, but DLK1 was lost from the fetal endothelial compartment of the null-TG placenta. However, DLK1 expression was retained in a small population of cells in the placental labyrinth; these cells had large nuclei, consistent with a trophoblast identity, and contributed 24% of Dlk1 expression in the wild-type state (Fig. 2d) . The placenta is a potential source of circulating DLK1 as, like the embryo, it expresses the cleavable Dlk1A and Dlk1B isoforms. As previously reported, the transgene recapitulated isoform-specific Dlk1 expression 11 (Fig. 2e) . We crossed null-TG fathers to null mothers to generate litters where all Dlk1 was derived from the transgene (Supplementary Fig. 2 ). We found that maternal circulating DLK1 levels were not different from those in wild type × wild type crosses ( Fig. 2f and Supplementary Table 1 ), indicating that DLK1 originates from either the embryo or a trophoblast population of the placenta.
We used a conditional allele of Dlk1 (ref. 20) to ablate expression in all cells of the embryo and the fetal endothelium of the placenta, using the Meox2-cre line 21 (Fig. 2g) . DLK1 was largely absent in the embryo when the conditional loxP-flanked allele (Dlk1 fl/fl ) was crossed onto the Meox2-cre background (Fig. 2h) . Confirmation that Meox2-cre was active in the fetal endothelium of the placenta was obtained by crossing mice from this line to an mTmG reporter line 22 (Fig. 2i) . As predicted, DLK1 expression in the placenta was absent from the fetal endothelial compartment in the conditional knockout line (Fig. 2i) . In the embryo and placenta, residual Dlk1 expression was 14-17% of wild-type levels following conditional targeting (Fig. 2j,k) . We crossed Meox2-cre +/− mothers to either wild-type or Dlk1 fl/fl fathers to generate litters where Dlk1 was undeleted or deleted in half of the litter (Supplementary Fig. 2 ; because the Meox2-cre allele is lethal in the homozygous state, we were unable to generate a fully deleted litter). We found that maternal circulating DLK1 levels in Dlk1-deleted litters were approximately 50% of those where Dlk1 was not deleted ( Fig. 2l and Supplementary Table 1 ), indicating that maternal circulating DLK1 does not originate from the trophoblast cells of the placenta. Taken together, these data indicate that the source of maternal circulating DLK1 is the embryo, not the placenta.
Pregnancies lacking DLK1 have compromised lipid metabolism
We next investigated whether Dlk1 expression dosage was relevant to the metabolic adaptations of pregnancy. Our experimental design allowed us to assess the contributions of both the maternal Dlk1 genotype and the presence or absence of circulating DLK1 from theconceptus (Fig. 1b) . During pregnancy, total body weight and food intake did not significantly differ between the groups (Supplementary Table 2 ), despite the larger litters in null females ( Fig. 1e and Supplementary Table 1 ). When weight gain was normalized for the number of conceptuses in the litter or total litter mass, null females gained relatively less weight over the course of pregnancy (Fig. 3a,b) . WAT, brown adipose tissue (BAT) and liver mass increased during pregnancy (Supplementary Table 3 ). Virgin and pregnant null females had enlarged abdominal WAT deposits in comparison to wild-type and Mat counterparts (Supplementary Table 3) ; however, consistent with their reduced overall weight gain, null females gained less WAT mass during pregnancy than Dlk1-expressing females (Fig. 3c) . This gain was depot specific, as null females had retroperitoneal WAT mass similar to that of Mat and wild-type females when virgins and females pregnant at E15.5 were examined. As in virgins, muscle mass was reduced in pregnant null females; brain mass did not differ between the groups (Supplementary Table 3 ). In summary, females lacking Dlk1 during their own development had altered body composition as virgins and gained less adipose tissue during pregnancy, suggesting that maternal loss of Dlk1 function limits adipose plasticity during pregnancy. Conceptus-derived circulating DLK1 did not modify any of these body composition parameters (Supplementary Tables 2 and 3 ).
In contrast, circulating DLK1 did modify the levels of circulating maternal metabolites. Whereas null × wild type females responded to pregnancy with a reduction in total cholesterol and HDL cholesterol (HDL-C) levels, pregnant null females lacking conceptusderived DLK1 (null × null) had a much less marked reduction in HDL-C levels (Supplementary Table 4 ). In addition, whereas Mat females with a normal pregnancy-induced increase in DLK1 levels had elevated levels of circulating ketones, Mat females without pregnancy-associated DLK1 did not. These changes occurred without alterations to circulating insulin levels (Supplementary Table 4 ) in freely fed females.
Upon fasting, null females without pregnancy-induced DLK1 production failed to elevate their circulating ketone levels and were relatively hyperglycemic, suggesting that the switch from glucose to fatty acid fuel use had not occurred (Fig. 3d,e) , despite normal insulin levels (Fig. 3f) . This notion was supported by the finding that null mothers with circulating DLK1 had elevated hepatic expression of Hmgcs2 (encoding a rate-limiting enzyme in the ketogenesis pathway; Fig. 3g ) in comparison to null mothers without circulating DLK1. As in non-fasted animals, null mothers without conceptusderived DLK1 did not experience the same magnitude of decrease in circulating HDL-C levels as null females with circulating DLK1 (Fig. 3h,i) . Combined, these data suggest that failure to elevate A DLK1 levels during pregnancy prevents normal maternal metabolic adaptations-specifically, reduced HDL-C levels and an accelerated response to starvation by the induction of ketogenesis. We previously reported that non-pregnant transgenic mice with DLK1 levels elevated to levels similar to those observed during pregnancy (DLK1 levels in Dlk1-transgenic females at 6 months of 343 ± 37 ng/ml compared to levels in wild type (× wild type) females at 12 weeks, E15.5, of 223 ± 24 ng/ml) have reduced circulating cholesterol levels and increased peripheral fatty acid use, in part because of increased GH production 11 . GH levels are elevated in pregnancy in both humans and rodents (although the source of rodent GH in pregnancy is not clear 23 , as rodents lack the placental GH gene variant found in primates 24 ). Because GH-like molecules promote maternal adaptations to pregnancy 24 , we asked whether circulating GH levels were affected by Dlk1 expression dose during gestation. GH levels were elevated 13-fold by E15.5 of pregnancy in wild-type mice, but pregnancies entirely lacking Dlk1 had a much less marked increase in GH levels (approximately 3-fold in the null × null cross; Fig. 3j ). These changes occurred in the absence of alterations to endocrine regulators of GH-estradiol and corticosterone (Fig. 3k,l) -and pituitary Gh mRNA levels were unaffected (Supplementary Fig. 3) . We conclude that pregnancies without a conceptus-derived increase in maternal plasma DLK1 levels have altered fuel metabolism, which may in part be due to impaired GH release.
Maternal circulating DLK1 levels associate with fetal growth
We compared the embryo and placental weights of conceptuses with similar genotypes in different maternal and litter contexts (Fig. 1b and  Supplementary Table 5) . Null embryos and placentae were smaller than wild-type and Mat counterparts, and neither the maternal genotype (and associated litter size) nor the presence/absence of circulating DLK1 affected weight at this stage (E15.5; Supplementary Table 5) . However, Mat embryos in mixed litters with null littermates (null × Mat crosses) were significantly larger than Mat and wild-type embryos in any other context (Supplementary Table 5 ). Interestingly, this group of conceptuses generated a greater amount of DLK1 per conceptus (Fig. 1e) , suggesting a direct link between embryonic size and maternal circulating DLK1 levels. Placental size was not similarly increased at this gestational stage (Supplementary Table 5) .
We therefore sought to determine whether there was any relationship between maternal plasma DLK1 levels and fetal growth in pregnant women. We used data and samples from a previously described prospective cohort, the Pregnancy Outcome Prediction study 25, 26 . A total of 4,512 women having first pregnancies were recruited, and Comparisons in a-c and j-l were made by one-way ANOVA with Bonferroni multiple-comparison post-hoc test: *P < 0.05, **P < 0.01. GH and corticosterone measures for pregnant and non-pregnant mice did not have equal variance, so only pregnant samples were compared. WT NP and WT × WT samples were compared using a Student's t test with Welch's correction: ***P < 0.001. Samples in d-i were compared by Student's t test: *P < 0.05, **P < 0.01, ***P < 0.001.
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VOLUME 48 | NUMBER 12 | DECEMBER 2016 Nature GeNetics A r t i c l e s outcome data were available from 4,200. We studied a sample of 45 women who delivered a baby with a customized birth weight percentile less than the 5th percentile (SGA) at term and had a plasma sample available, which had been obtained around 36 weeks of gestational age (wkGA). We then identified two comparison groups: (i) matched controls (available for 43 of the 45 cases) and (ii) a random sample from the cohort. In the former comparison group, women were matched one to one on the basis of maternal age, BMI, smoking status, fetal sex and mode of delivery to controls delivering a normally grown infant; that is, samples were analyzed as a matched case-control study 27 . The maternal and outcome characteristics of these three groups are tabulated in Supplementary Table 6 . Analysis of the matched cases and controls indicated no significant differences between the groups in either the matching characteristics or the gestational age at which DLK1 levels were measured (Supplementary Table 7 ). However, in comparison with the matched controls, cases had infants whose birth weight was 820 g lower on average. Different SGA phenotypes were classified according to research ultrasonographic examination 26 . Ultrasonic assessment included serial Doppler flow velocimetry of the uterine and umbilical arteries. Both women and clinicians were blinded to the results of these research scans. High-resistance uterine artery flow was defined as a mean pulsatility index in the top decile at 20 wkGA, high-resistance umbilical artery flow was defined as a pulsatility index in the top decile at 36 wkGA and low abdominal circumference growth velocity was defined as a z score for the difference in abdominal circumference between the scans at 36 and 20 wkGA falling in the lowest decile (this group included the fetuses showing the greatest reduction in relative abdominal circumference at the time of the scan at 36 wkGA). Among the 43 SGA pregnancies with matched controls, 20 (47%) had none of these features and were called healthy SGA and 23 (53%) had one or more of these features and were defined as FGR (the birth outcomes of these two groups are presented in Supplementary Table 8) . DLK1 levels were measured in maternal plasma obtained at a mean of 36 weeks and 1 d of gestational age (s.d. = 2.7 d) (Fig. 4a) . When compared with matched controls (Supplementary Table 9) , women with SGA infants had lower DLK1 levels overall (mean difference = −9.44, P = 0.0001). However, when this population was divided into mothers with healthy SGA and FGR infants, there was no significant difference in DLK1 levels between mothers with healthy SGA infants and controls (mean difference = −4.97, P = 0.22), but there was a highly statistically significant reduction in DLK1 levels in mothers with FGR infants relative to controls (mean difference = −13.33, P < 0.0001). When analysis was performed with the different FGR phenotypes, there were very strong associations between DLK1 concentration and SGA in the presence of either highresistance umbilical artery flow by Doppler (mean difference = −17.13, P < 0.0001) or low abdominal circumference growth velocity (mean difference = −11.96, P = 0.007).
The strength of the association was then further evaluated by comparing cases with the random sample of the cohort using receiver operating characteristic (ROC) curve analysis (Fig. 4b) . Overall, DLK1 levels were moderately predictive of SGA: area under the ROC curve (AUROCC) = 0.65 (95% confidence interval (CI) = 0.54-0.77; P = 0.01). Similarly to the comparison with matched controls, there was no significant association between DLK1 levels and healthy SGA (AUROCC = 0.59, 95% CI = 0.44-0.74; P = 0.22), but there was a highly statistically significant association of DLK1 levels with FGR (AUROCC = 0.71, 95% CI = 0.58-0.84; P = 0.001). Again, the strongest association was with SGA combined with high-resistance umbilical artery flow by Doppler (AUROCC = 0.82, 95% CI = 0.70-0.93; P < 0.0001).
DISCUSSION
During late pregnancy, the mother must be able to adapt her metabolism to changes in food availability to maintain a constant supply of energy to the fetus. Here we have shown in the mouse that both DLK1 expression in maternal tissues and circulating DLK1 derived from the fetus are necessary for appropriate metabolic adaptations to pregnancy, specifically to provide metabolic plasticity by allowing the switch to fatty acid use when resources are limited during fasting.
Moreover, as it is derived from the fetus, maternal circulating DLK1 provides a noninvasive readout of embryonic state. Our data indicate that maternal plasma DLK1 levels are lower in pregnancies complicated by FGR and suggest that DLK1 measurements in women may be clinically useful to differentiate healthy SGA infants from those who are pathologically small, an area of intense clinical interest. Interestingly, lower DLK1 levels were most strongly associated with high-resistance patterns of flow in the umbilical artery and slow abdominal circumference growth velocity. The potential clinical relevance of clinical measurement of DLK1 concentration is underlined by the fact that we have previously reported that these two measures were the most effective predictors of neonatal morbidity in pregnancies where the baby was suspected to be small on the basis of ultrasonic fetal biometry 26 . Previous studies have reported contradictory associations between cord blood DLK1 levels and birth weight 28 , and low DLK1 was associated with complications of pregnancy 29 . Those studies used a commercial ELISA that reports DLK1 levels ~100 times lower than those reported in the original pioneering work on DLK1 as a soluble factor in pregnancy 7 and the values measured in this study. This suggests that further assay development may be required before DLK1 is a suitable biomarker for clinical use. However, our data are consistent with a recent study that reported a genomic variant at the imprinted DLK1-MEG3 locus in humans that segregates with birth weight 30 and with a study where elevated DLK1 expression was detected in pregnancies resulting in infants born large for gestational age 31 .
The analysis of human plasma samples was focused on blood samples obtained at 36 wkGA. The gestational age for analysis was purposeful, as at this stage of pregnancy delivery is a safe and effective intervention to mitigate the risks of FGR where it is clinically suspected. We have previously outlined a case for screening women for adverse pregnancy outcome in late gestation 32 ; around one-third of all intrauterine fetal deaths (IUFDs) occur at or after 37 wkGA, and about 30% of all IUFDs at term are thought to be related to poor fetal growth 12 . However, detection of FGR at earlier gestational ages would also be valuable, and further work could address whether the associations we found are present at earlier gestational ages and whether DLK1 is also predictive of other adverse pregnancy outcomes.
In conclusion, our findings highlight DLK1 measurement as a valuable prenatal diagnostic for known disorders of impaired fetal DLK1 production (such as Temple syndrome 33 ) and indicate that measuring maternal plasma DLK1 may have more general utility in differentiating healthy SGA pregnancies from pathological complications of pregnancy requiring obstetric intervention.
METhODS
Methods and any associated references are available in the online version of the paper.
